Loading...
•
Sep 30, 2024
Surmodics Q4 2024 Earnings Report
Surmodics reported strong Q4 2024 financial results with revenue growth and advancements in medical device segment.
Key Takeaways
Surmodics reported a 19% year-over-year increase in total revenue for Q4 2024, driven by strong performance in the Medical Device segment. The company's GAAP net loss was $(3.4) million, while adjusted EBITDA reached $4.4 million.
Total revenue increased by 19% year-over-year to $33.2 million.
Medical Device revenue grew by 22% to $25.8 million, driven by vascular interventional products and performance coating reagents.
GAAP net loss was $(3.4) million, compared to net income of $6.7 million in the prior-year period.
Adjusted EBITDA was $4.4 million, compared to $1.7 million in the prior-year period.
Surmodics
Surmodics
Surmodics Revenue by Segment
Revenue by Segment
Medical Device Revenue
CapyFin.comIn Vitro Diagnostics Revenue
CapyFin.com Forward Guidance
Surmodics is not introducing financial guidance for fiscal year 2025 due to the pending acquisition by GTCR.
Revenue & Expenses
Visualization of income flow from segment revenue to net income